Description_x000D_ Application_x000D_ Spironolactone was added to rat diet to study the effect of long-term spironolactone use on renal function._x000D_ Packaging_x000D_ 1, 5 g in glass bottle_x000D_ Biochem/physiol Actions_x000D_ Spironolactone reduces aldosterone-induced potassium/magnesium loss and myocardial fibrosis. It reduces hypertension, improves the endothelial function and reduces the overall morbidity and mortality in patients with chronic heart failure. Spironolactone improves nitric oxide bioactivity and vascular endothelial vasodilator dysfunction._x000D_ Spironolactone is a competitive aldosterone receptor antagonist. Used as potassium sparing diuretic._x000D_ Features and Benefits_x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more._x000D_ This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here._x000D_ This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Preparation Note_x000D_ Spironolactone yields clear, faint yellow solution in chloroform at 50 mg/ml._x000D_ Other Notes_x000D_ Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. S3378.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin._x000D_ Legal Information_x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC